TScan Therapeutics (TCRX) Stock Forecast, Price Target & Predictions
TCRX Stock Forecast
TScan Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 172.11% upside from TCRX’s last price of $4.41) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
TCRX Price Target
The average price target for TScan Therapeutics (TCRX) is $12.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 172.11% upside from TCRX's last price of $4.41.
TCRX Analyst Ratings
According to 2 Wall Street analysts, TScan Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TCRX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TScan Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Justin Zelin | BTIG | $12.00 | $8.93 | 34.38% | 172.11% |
The latest TScan Therapeutics stock forecast, released on May 16, 2024 by Justin Zelin from BTIG, set a price target of $12.00, which represents a 34.38% increase from the stock price at the time of the forecast ($8.93), and a 172.11% increase from TCRX last price ($4.41).
TScan Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $4.41 | $4.41 | $4.41 |
| Upside/Downside | -100.00% | -100.00% | 172.11% |
In the current month, the average price target of TScan Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TScan Therapeutics's last price of $4.41. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 13, 2024 | Needham | Underperform | Underperform | Hold |
| Jun 04, 2024 | Needham | Underperform | Underperform | Hold |
| Jun 04, 2024 | Wedbush | Buy | Buy | Hold |
| May 16, 2024 | BTIG | - | Buy | Initialise |
| May 13, 2024 | Wedbush | Buy | Buy | Hold |
| May 13, 2024 | Needham | Underperform | Underperform | Hold |
TScan Therapeutics's last stock rating was published by Wedbush on Aug 13, 2024. The company gave TCRX a "Buy" rating, the same as its previous rate.
TScan Therapeutics Financial Forecast
TScan Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $7.21M | - | - | $6.80M | $1.00K | $3.36M | $4.06M | $3.02M | $2.85M | $2.41M | $2.85M |
| Avg Forecast | $1.38M | $1.38M | $1.38M | $1.38M | $1.51M | $1.17M | $1.80M | $3.98M | $3.45M | $4.45M | $4.37M | $4.87M | $4.10M | $3.93M | $3.00M | $2.76M | $3.47M | $3.48M | $3.37M |
| High Forecast | $2.73M | $2.73M | $2.73M | $2.73M | $3.77M | $1.18M | $3.56M | $4.14M | $5.40M | $4.45M | $8.65M | $9.63M | $8.10M | $3.93M | $3.00M | $2.76M | $3.47M | $3.48M | $3.37M |
| Low Forecast | $506.33K | $506.33K | $506.33K | $506.33K | $143.93K | $1.17M | $659.83K | $3.81M | $2.03M | $4.45M | $1.60M | $1.78M | $1.50M | $3.93M | $3.00M | $2.76M | $3.47M | $3.48M | $3.37M |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 2.09% | - | - | 1.40% | 0.00% | 0.86% | 1.35% | 1.10% | 0.82% | 0.69% | 0.85% |
TScan Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $3.98M, with a low forecast of $3.81M, and a high forecast of $4.14M. TCRX's average Quarter revenue forecast represents a -44.88% decrease compared to the company's last Quarter revenue of $7.21M (Dec 23).
TScan Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-20.08M | $-24.75M | $-24.61M | $-21.61M | $-17.75M | $-14.79M | $-14.04M | $-16.16M | $-13.06M | $-14.78M | $-10.01M |
| Avg Forecast | $-828.75K | $-828.75K | $-828.75K | $-828.75K | $-906.00K | $-703.56K | $-1.08M | $-2.38M | $-2.07M | $-2.67M | $-2.62M | $-2.92M | $-2.46M | $-2.36M | $-1.80M | $-1.65M | $-2.08M | $-2.09M | $-7.44M |
| High Forecast | $-303.80K | $-303.80K | $-303.80K | $-303.80K | $-86.36K | $-699.84K | $-395.90K | $-2.29M | $-1.22M | $-2.67M | $-962.10K | $-1.07M | $-901.25K | $-2.36M | $-1.80M | $-1.65M | $-2.08M | $-2.09M | $-5.96M |
| Low Forecast | $-1.64M | $-1.64M | $-1.64M | $-1.64M | $-2.26M | $-707.28K | $-2.13M | $-2.48M | $-3.24M | $-2.67M | $-5.19M | $-5.78M | $-4.86M | $-2.36M | $-1.80M | $-1.65M | $-2.08M | $-2.09M | $-8.93M |
| Surprise % | - | - | - | - | - | - | - | - | 9.69% | 9.27% | 9.38% | 7.40% | 7.22% | 6.27% | 7.79% | 9.78% | 6.28% | 7.08% | 1.35% |
undefined analysts predict TCRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than TScan Therapeutics's previous annual EBITDA (undefined) of $NaN.
TScan Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-19.61M | $-23.00M | $-24.05M | $-23.34M | $-18.80M | $-15.91M | $-14.95M | $-16.15M | $-14.20M | $-15.84M | $-10.67M |
| Avg Forecast | $-32.89M | $-33.18M | $-32.61M | $-31.76M | $-33.18M | $-35.77M | $-32.08M | $-29.40M | $-32.80M | $-51.34M | $-86.77M | $-78.55M | $-82.12M | $-82.35M | $-84.39M | $-79.40M | $-79.40M | $-68.62M | $-7.94M |
| High Forecast | $-5.81M | $-5.86M | $-5.76M | $-5.61M | $-28.44M | $-6.31M | $-5.66M | $-5.19M | $-28.43M | $-9.06M | $-15.32M | $-13.87M | $-14.50M | $-82.35M | $-84.39M | $-79.40M | $-79.40M | $-68.62M | $-6.35M |
| Low Forecast | $-74.66M | $-75.31M | $-74.02M | $-72.09M | $-39.10M | $-81.19M | $-72.83M | $-66.73M | $-48.11M | $-116.53M | $-196.96M | $-178.29M | $-186.40M | $-82.35M | $-84.39M | $-79.40M | $-79.40M | $-68.62M | $-9.52M |
| Surprise % | - | - | - | - | - | - | - | - | 0.60% | 0.45% | 0.28% | 0.30% | 0.23% | 0.19% | 0.18% | 0.20% | 0.18% | 0.23% | 1.34% |
TScan Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TCRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TScan Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $4.88M | $5.89M | $6.53M | $7.77M | $6.14M | $4.91M | $4.81M | $4.49M | $4.45M | $4.05M | $2.73M |
| Avg Forecast | $3.13M | $3.13M | $3.13M | $3.13M | $3.42M | $2.66M | $4.08M | $9.01M | $7.83M | $10.09M | $9.91M | $11.04M | $9.29M | $8.71M | $6.65M | $6.10M | $7.68M | $7.71M | $2.03M |
| High Forecast | $6.19M | $6.19M | $6.19M | $6.19M | $8.55M | $2.67M | $8.06M | $9.38M | $12.25M | $10.09M | $19.60M | $21.82M | $18.36M | $8.71M | $6.65M | $6.10M | $7.68M | $7.71M | $2.43M |
| Low Forecast | $1.15M | $1.15M | $1.15M | $1.15M | $326.20K | $2.64M | $1.50M | $8.64M | $4.61M | $10.09M | $3.63M | $4.05M | $3.40M | $8.71M | $6.65M | $6.10M | $7.68M | $7.71M | $1.62M |
| Surprise % | - | - | - | - | - | - | - | - | 0.62% | 0.58% | 0.66% | 0.70% | 0.66% | 0.56% | 0.72% | 0.74% | 0.58% | 0.53% | 1.35% |
TScan Therapeutics's average Quarter SG&A projection for Mar 24 is $9.01M, based on 1 Wall Street analysts, with a range of $8.64M to $9.38M. The forecast indicates a 84.54% rise compared to TCRX last annual SG&A of $4.88M (Dec 23).
TScan Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.21 | $-0.00 | $-0.00 | $-0.96 | $-0.78 | $-0.66 | $-0.62 | $-0.67 | $-0.71 | $-0.80 | $-0.45 |
| Avg Forecast | $-0.29 | $-0.29 | $-0.29 | $-0.28 | $-0.29 | $-0.32 | $-0.28 | $-0.26 | $-0.29 | $-0.45 | $-0.77 | $-0.69 | $-0.72 | $-0.73 | $-0.74 | $-0.70 | $-0.70 | $-0.60 | $-0.65 |
| High Forecast | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.25 | $-0.06 | $-0.05 | $-0.05 | $-0.25 | $-0.08 | $-0.14 | $-0.12 | $-0.13 | $-0.73 | $-0.74 | $-0.70 | $-0.70 | $-0.60 | $-0.65 |
| Low Forecast | $-0.66 | $-0.66 | $-0.65 | $-0.64 | $-0.34 | $-0.72 | $-0.64 | $-0.59 | $-0.42 | $-1.03 | $-1.74 | $-1.57 | $-1.64 | $-0.73 | $-0.74 | $-0.70 | $-0.70 | $-0.60 | $-0.65 |
| Surprise % | - | - | - | - | - | - | - | - | 0.73% | 0.00% | 0.00% | 1.39% | 1.08% | 0.91% | 0.83% | 0.96% | 1.01% | 1.32% | 0.70% |
According to undefined Wall Street analysts, TScan Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TCRX previous annual EPS of $NaN (undefined).
TScan Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.40 | $3.67 | 817.50% | Buy |
| DRMA | Dermata Therapeutics | $1.12 | $6.00 | 435.71% | Buy |
| INZY | Inozyme Pharma | $3.13 | $14.67 | 368.69% | Buy |
| ITOS | iTeos Therapeutics | $8.23 | $37.67 | 357.72% | Buy |
| CUE | Cue Biopharma | $1.25 | $4.33 | 246.40% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.40 | $7.00 | 191.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| TCRX | TScan Therapeutics | $4.41 | $12.00 | 172.11% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $18.57 | $45.38 | 144.37% | Buy |
| TERN | Terns Pharmaceuticals | $6.17 | $14.25 | 130.96% | Buy |
| ANNX | Annexon | $6.12 | $14.00 | 128.76% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| PRQR | ProQR Therapeutics | $3.82 | $3.63 | -4.97% | Buy |